Use of ultra performance liquid chromatography for high throughput screening in pharmaceutical development

ANYL 149

Panagiota Rizos, panagiota_rizos@merck.com1, Mohammad A. Al-Sayah, mohammed_al-sayah@merck.com1, and Vincent Antonucci2. (1) Early Development- Analytical Research, Merck and Company, Inc, 126 East Lincoln Avenue, RY818-C207, Rahway, NJ 07065/0900, (2) Early Development- Analytical Research, Merck & Company, Inc, 126 East Lincoln Avenue, RY818-C220, Rahway, NJ 07065/0900
The demands of the pharmaceutical industry to decrease costs and shorten timelines as the number of preclinical candidates (PCC's) increases, require the implementation of high throughput chromatographic methods. Each PCC arises from a unique chemical process and possesses distinct properties necessitating compound-specific, labor-intensive traditional column screening methodology. Ultra Performance Liquid Chromatography (UPLC) operating at pressures as high as 15,000 psi was evaluated as a potential means to increase method development throughput. Approximately twenty active pharmaceutical ingredients (API) were screened using C-18 and phenyl stationary phases packed with 1.7 micron particles with standard mobile phase gradients. The UPLC selectivity results were compared to those obtained via conventional HPLC methods demonstrating that simple, high efficiency UPLC gradients are a viable and productive substitute. Furthermore, efficiency gain with increasing theoretical plates was evaluated. An analysis of time, cost and resource savings was conducted showing the extensive business benefits that could be achieved.
 

General Papers
7:00 PM-9:00 PM, Sunday, 10 September 2006 Moscone Center -- Hall D, Poster

Division of Analytical Chemistry

The 232nd ACS National Meeting, San Francisco, CA, September 10-14, 2006